InMed Pharmaceuticals INM
NASDAQ INM
$1.57 -0.02 (-1.26%)
As of: Aug 20, 2026 · 3:50 PM EDT

InMed Pharmaceuticals (INM) Total Debt (2021 - 2022)

InMed Pharmaceuticals (INM) posted quarterly Total Debt of $29312.0 for Q1 2022, down 50.0% quarter-over-quarter from $58624.0 in Q4 2021.

InMed Pharmaceuticals (INM) Total Debt (2021 - 2022) Analysis & Trends

InMed Pharmaceuticals' Total Debt history runs 2 years deep, the most recent figure standing at $29312.0 for Q1 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Haleon 43.85 Bn 42.88 Bn - -5.81 Bn
2 Teva Pharmaceutical Industries 43.02 Bn 39.37 Bn 2.15 Bn 16.59 Bn
3 Zoetis 31.47 Bn 29.79 Bn 1.05 Bn 9.05 Bn
4 Takeda Pharmaceutical 28.59 Bn 22.79 Bn 5.10 Bn 31.47 Bn
5 United Therapeutics 22.20 Bn 19.53 Bn 683.80 Mn -
6 Viatris 18.76 Bn 17.87 Bn 1.46 Bn 13.35 Bn
7 Neurocrine Biosciences 15.45 Bn 15.06 Bn 935.80 Mn -
8 Elanco Animal Health 11.76 Bn 11.23 Bn 798.00 Mn 3.92 Bn
9 Dr Reddys Laboratories 10.10 Bn 9.94 Bn - 760.00 Mn
10 InMed Pharmaceuticals 6.36 Mn 1.11 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2022 29,312.00
Dec 31, 2021 58,624.00